{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:31:12Z","timestamp":1785339072184,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Leon","doi-asserted-by":"publisher","award":["SA074P20"],"award-info":[{"award-number":["SA074P20"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["2023\/2027"],"award-info":[{"award-number":["2023\/2027"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"COST","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00189"],"award-info":[{"award-number":["PI20\/00189"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00819"],"award-info":[{"award-number":["PI19\/00819"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Marathon Foundation of Tv3","doi-asserted-by":"publisher","award":["201916-31"],"award-info":[{"award-number":["201916-31"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI22\/01427"],"award-info":[{"award-number":["PI22\/01427"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"publisher","award":["PC_TCUE21\\u201323_011"],"award-info":[{"award-number":["PC_TCUE21\\u201323_011"]}],"id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"publisher","award":["PIC2-2021-11"],"award-info":[{"award-number":["PIC2-2021-11"]}],"id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["EHD22PI01"],"award-info":[{"award-number":["EHD22PI01"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.biopha.2023.116038","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T12:50:55Z","timestamp":1703249455000},"page":"116038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with \u03b2-caryophyllene oxide"],"prefix":"10.1016","volume":"170","author":[{"given":"Sara","family":"Ortiz-Rivero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Peleteiro-Vigil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Abete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Di","family":"Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"P\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.biopha.2023.116038_bib1","first-page":"19","article-title":"Cholangiocarcinoma: Epidemiology and risk factors, Liver international: official journal of the International Association for the Study of the Liver","volume":"39","author":"Khan","year":"2019"},{"issue":"9","key":"10.1016\/j.biopha.2023.116038_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116038_bib3","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.biopha.2023.116038_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116038_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.hpb.2017.08.025","article-title":"Koerkamp, The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma","volume":"20","author":"van Vugt","year":"2018","journal-title":"HPB: Off. J. Int. Hepato Pancreato Biliary Assoc."},{"issue":"6","key":"10.1016\/j.biopha.2023.116038_bib6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.116038_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10391","key":"10.1016\/j.biopha.2023.116038_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"G. Advanced Biliary Cancer Working, Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116038_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041244","article-title":"New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy","volume":"15","author":"Mauro","year":"2023","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.biopha.2023.116038_bib12","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.116038_bib13","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2023.116038_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2023.116038_bib15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.116038_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/imt-2022-0225","article-title":"Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma","volume":"15","author":"Skouteris","year":"2023","journal-title":"Immunotherapy"},{"issue":"4 Pt B","key":"10.1016\/j.biopha.2023.116038_bib17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbadis.2017.06.005","article-title":"Chemoresistance and chemosensitization in cholangiocarcinoma, Biochimica et biophysica acta","volume":"1864","author":"Marin","year":"2018","journal-title":"Mol. Basis Dis."},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":", Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116038_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010149","article-title":"Autocrine and paracrine mechanisms promoting chemoresistance in cholangiocarcinoma","volume":"18","author":"Cadamuro","year":"2017","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2023.116038_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102358","article-title":"Novel pharmacological options in the treatment of cholangiocarcinoma: mechanisms of resistance","volume":"13","author":"Marin","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2023.116038_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0041-1735631","article-title":"Mechanisms of pharmacoresistance in hepatocellular carcinoma: new drugs but old problems","volume":"42","author":"Marin","year":"2022","journal-title":"Semin. liver Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.116038_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2011.08.001","article-title":"beta-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K\/AKT\/mTOR\/S6K1 pathways and ROS-mediated MAPKs activation","volume":"312","author":"Park","year":"2011","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.biopha.2023.116038_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/mc.22035","article-title":"beta-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase","volume":"53","author":"Kim","year":"2014","journal-title":"Mol. Carcinog."},{"issue":"11","key":"10.1016\/j.biopha.2023.116038_bib24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/tox.22136","article-title":"Mutagenicity of cigarette butt waste in the bacterial reverse mutation assay: the protective effects of beta-caryophyllene and beta-caryophyllene oxide","volume":"31","author":"Di Giacomo","year":"2016","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.biopha.2023.116038_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/596312","article-title":"In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid","volume":"2014","author":"Fiorenzani","year":"2014","journal-title":"Evid. -Based Complement. Altern. Med.: eCAM"},{"issue":"3","key":"10.1016\/j.biopha.2023.116038_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.21873\/anticanres.11433","article-title":"Chemosensitizing properties of beta-caryophyllene and beta-caryophyllene oxide in combination with doxorubicin in human cancer cells","volume":"37","author":"Di Giacomo","year":"2017","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.116038_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00204-019-02395-9","article-title":"Chemosensitization of hepatocellular carcinoma cells to sorafenib by beta-caryophyllene oxide-induced inhibition of ABC export pumps","volume":"93","author":"Di Giacomo","year":"2019","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116038_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/mol.111.075143","article-title":"Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta","volume":"81","author":"Blazquez","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2023.116038_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.08.022","article-title":"Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)","volume":"216","author":"Lozano","year":"2015","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"6","key":"10.1016\/j.biopha.2023.116038_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/pmic.200800842","article-title":"Proteome wide screening using peptide affinity capture","volume":"9","author":"Poetz","year":"2009","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/j.biopha.2023.116038_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/dmd.117.078626","article-title":"Direct quantification of cytochromes P450 and drug transporters-A rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates","volume":"46","author":"Weiss","year":"2018","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.biopha.2023.116038_bib32","first-page":"1053","article-title":"Okadaic acid influences xenobiotic metabolism in HepaRG cells","volume":"21","author":"Wuerger","year":"2022","journal-title":"EXCLI J."},{"issue":"9","key":"10.1016\/j.biopha.2023.116038_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1369\/jhc.5A6912.2006","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) is expressed by progenitor cells\/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences","volume":"54","author":"Vander Borght","year":"2006","journal-title":"J. Histochem. Cytochem."},{"issue":"7","key":"10.1016\/j.biopha.2023.116038_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.biopha.2023.116038_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143524","article-title":"Expression of chemoresistance-associated ABC proteins in hepatobiliary, pancreatic and gastrointestinal cancers","volume":"14","author":"Marin","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.biopha.2023.116038_bib37","first-page":"577","article-title":"Thymosin beta10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma","volume":"15","author":"Sribenja","year":"2016","journal-title":"Ann. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.116038_bib38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3892\/or.2014.3123","article-title":"Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro","volume":"31","author":"Wu","year":"2014","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2023.116038_bib39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/labinvest.3700127","article-title":"Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium","volume":"84","author":"Aust","year":"2004","journal-title":"Lab. Invest"},{"issue":"8","key":"10.1016\/j.biopha.2023.116038_bib40","doi-asserted-by":"crossref","first-page":"15343","DOI":"10.3390\/molecules200815343","article-title":"The influence of sesquiterpenes from myrica rubra on the antiproliferative and pro-oxidative effects of doxorubicin and its accumulation in cancer cells","volume":"20","author":"Ambroz","year":"2015","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2006-957932","article-title":"Cytotoxic and antioxidative sesquiterpenoids from Heterotheca inuloides","volume":"62","author":"Kubo","year":"1996","journal-title":"Planta Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.116038_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.31088","article-title":"MRP3-mediated chemoresistance in cholangiocarcinoma: target for chemosensitization through restoring SOX17 expression","volume":"72","author":"Lozano","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2023.116038_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700686","article-title":"Bioprocessing of recombinant CHO-K1, CHO-DG44, and CHO-S: CHO expression hosts favor either mAb production or biomass synthesis","volume":"14","author":"Reinhart","year":"2019","journal-title":"Biotechnol. J."},{"issue":"18","key":"10.1016\/j.biopha.2023.116038_bib44","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.116038_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3892\/mco.2013.143","article-title":"Expression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens","volume":"1","author":"Wang","year":"2013","journal-title":"Mol. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.116038_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083627","article-title":"BCRP\/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.biopha.2023.116038_bib47","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1021\/mp300178a","article-title":"Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins","volume":"9","author":"Herraez","year":"2012","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.116038_bib48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yrtph.2013.04.006","article-title":"Genotoxicity assessment of beta-caryophyllene oxide","volume":"66","author":"Di Sotto","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"19","key":"10.1016\/j.biopha.2023.116038_bib49","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1158\/0008-5472.CAN-04-1005","article-title":"Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance","volume":"64","author":"Munoz-Martinez","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2023.116038_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116038_bib51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/dmd.114.062174","article-title":"Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design","volume":"43","author":"Lee","year":"2015","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.biopha.2023.116038_bib52","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/978-981-13-7647-4_11","article-title":"Contributions of drug transporters to blood-placental barrier","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"13","key":"10.1016\/j.biopha.2023.116038_bib53","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301836X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301836X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:19:31Z","timestamp":1778541571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222301836X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":53,"alternative-id":["S075333222301836X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116038","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with \u03b2-caryophyllene oxide","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116038"}}